CNS PHARMACEUTICALS, INC. | Item 7.01 | Regulation FD Disclosure |
On October 18, 2023, CNS Pharmaceuticals, Inc. (the "Company"), posted a Virtual Investor event video with the Company's Chief Executive Officer, John Climaco, discussing the Company's Berubicin clinicial trial.
A link to the call may be found at https://www.virtualinvestorco.com/wtmcnsp and is incorporated by reference herein.
The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended ("Securities Act"), unless specifically identified therein as being incorporated by reference.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
CNS Pharmaceuticals Inc. published this content on 18 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 October 2023 14:19:32 UTC.
